Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Dec 31 · Reports in EUR
Net income was −EUR 176M. Operating cash flow of −EUR 137M less capital expenditure of EUR 164,619 left free cash flow of −EUR 137M.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Research & development | 35.8 | 57.4 | 65.6 | 98.6 | 124 |
| Operating income | −42.7 | −75.7 | −99.8 | −132 | −174 |
| Interest expense | 0.3 | 0.0 | – | – | – |
| Pre-tax income | −42.7 | −75.7 | −99.8 | −132 | −174 |
| Income tax | 0.1 | 0.7 | 1.0 | 1.8 | 2.0 |
| Net income | −42.7 | −76.3 | −101 | −134 | −176 |
| Diluted EPS | −1.40 | −2.27 | −2.63 | −2.48 | −2.97 |
| Diluted shares | 30.4 | 33.6 | 38.4 | 54.0 | 59.2 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 209 | 162 | 391 | 281 | 292 |
| Receivables | 0.7 | 0.4 | 1.0 | 2.9 | 4.6 |
| Net PP&E | 0.1 | 0.2 | 0.2 | 0.7 | 0.6 |
| Total assets | 212 | 168 | 399 | 291 | 301 |
| Payables | 2.5 | 6.7 | 2.9 | 4.6 | 5.1 |
| Total liabilities | 7.1 | 18.5 | 14.6 | 23.6 | 30.2 |
| Shareholders' equity | 205 | 149 | 384 | 268 | 271 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | −44.6 | −67.2 | −93.0 | −120 | −137 |
| Capital expenditure | 0.1 | 0.1 | 0.1 | 0.5 | 0.2 |
| Free cash flow | −44.7 | −67.3 | −93.1 | −121 | −137 |
| Stock-based compensation | 7.0 | 7.6 | 6.2 | 10.5 | 11.2 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Return on equityBlank when equity is negative | −20.8% | −51.1% | −26.3% | −50.1% | −64.8% |
| Cash conversion (CFO ÷ net income) | 1.04x | 0.88x | 0.92x | 0.90x | 0.78x |
| Interest cover | −159x | −4698x | – | – | – |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.